# C4 Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/c4-therapeutics

- Industry: Biotechnology
- Headquarters: Watertown, US
- Website: www.c4therapeutics.com
- Total disclosed funding: $220M
- Latest round: Series B (May 29, 2020)
- Investors on record: 24

## About

C4 Therapeutics, Inc. is a US-based biotechnology firm focused on developing innovative therapies using Targeted Protein Degradation (TPD) to treat cancer and serious diseases, aiming to transform patient outcomes through its proprietary technologies.Founded in 2016 and headquartered in Watertown, US, C4 Therapeutics, Inc. specializes in developing targeted therapies. The company has secured a total of 4 deals and its most recent deal was an IPO on October 1, 2020, raising USD 182.40 mn. The IPO involved selling 9.60 million shares at USD 19 per share. The CEO is Andrew Hirsch, and Marc Cohen is the founder.C4 Therapeutics specializes in innovative therapeutic solutions centered on Targeted Protein Degradation (TPD), particularly through its proprietary TORPEDO® platform. Their investigational drugs, including Cemsidomide, CFT8919, and CFT1946, focus on selectively degrading disease-causing proteins to address unmet needs in oncology and serious diseases. The company’s offerings aim to improve patient outcomes by minimizing off-target effects typical of conventional therapies. Their clientele mainly comprises healthcare providers and research institutions across North America and Europe, targeting patients with various cancers and autoimmune disorders.In 2023, C4 Therapeutics reported a revenue of USD 20.76 mn. However, the company also faced an EBITDA loss of USD 136.75 mn during the same year, reflecting the ongoing investment in the development of its therapeutic products.C4 Therapeutics plans to leverage the proceeds from its recent IPO to advance multiple degrader drug candidates to human proof-of-concept, thereby enhancing its development pipeline. The company aims to expand its market presence, particularly in North America and Europe, as it works to bring new products to market. The funding raised will support these initiatives and strengthen their capabilities in TPD.

## Funding rounds

- Series B, May 29, 2020, $150M — Bain Capital, T Rowe Price, HBM Partners, Adage Capital Management, Nextech, Janus Henderson Investors, RTW Investments, RA Capital Management, Perceptive Advisors, Sphera Funds Management, Cobro Ventures, Mizuho Securities Principal Investment, 3E Bioventures Capital, Taiwania Capital, Axil Capital, Lightchain Capital, Commodore Capital, Logos Capital, Yonjin Venture
- Series A, Jan 7, 2016, $70M — EG Capital Group, Kraft Group, Cormorant Asset Management, Roche Holding Ltd, Novartis, Cobro Ventures

## Investors

- EG Capital Group (https://capitalatlas.ai/funds/eg-capital-group) — Series A
- Kraft Group — Series A
- Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Series A
- Roche Holding Ltd — Series A
- Novartis — Series A
- Cobro Ventures (https://capitalatlas.ai/funds/cobro-ventures) — Series A, Series B
- Bain Capital (https://capitalatlas.ai/funds/bain-capital) — Series B
- T Rowe Price (https://capitalatlas.ai/funds/t-rowe-price) — Series B
- HBM Partners (https://capitalatlas.ai/funds/hbm-partners) — Series B
- Adage Capital Management — Series B
- Nextech (https://capitalatlas.ai/funds/nextech) — Series B
- Janus Henderson Investors — Series B
- RTW Investments (https://capitalatlas.ai/funds/rtw-investments) — Series B
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series B
- Perceptive Advisors (https://capitalatlas.ai/funds/perceptive-advisors) — Series B
- Sphera Funds Management — Series B
- Mizuho Securities Principal Investment (https://capitalatlas.ai/funds/mizuho-securities-principal-investment) — Series B
- 3E Bioventures Capital (https://capitalatlas.ai/funds/3e-bioventures-capital) — Series B
- Taiwania Capital (https://capitalatlas.ai/funds/taiwania-capital) — Series B
- Axil Capital (https://capitalatlas.ai/funds/axil-capital) — Series B
- Lightchain Capital (https://capitalatlas.ai/funds/lightchain-capital) — Series B
- Commodore Capital (https://capitalatlas.ai/funds/commodore-capital) — Series B
- Logos Capital (https://capitalatlas.ai/funds/logos-capital) — Series B
- Yonjin Venture (https://capitalatlas.ai/funds/yonjin-venture) — Series B